The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Hereditary Angioedema Therapeutics Market During 2026–2030?
The hereditary angioedema therapeutics market size has seen rapid expansion in recent years. It is anticipated to grow from $7.77 billion in 2025 to $9.27 billion in 2026, achieving a compound annual growth rate (CAGR) of 19.3%. During the historical period, this growth was driven by factors including limited awareness about HAE, reliance on hospital-based therapy, a scarcity of approved therapeutic options, the need for intravenous administration, and low prevalence diagnosis rates.
The hereditary angioedema therapeutics market is projected to experience substantial expansion in the coming years, reaching a valuation of $19.03 billion by 2030, propelled by a compound annual growth rate (CAGR) of 19.7%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing development of recombinant C1 esterase inhibitors, the widespread adoption of subcutaneous delivery methods, the escalating use of prophylactic therapies, the broadening reach of specialty pharmacy channels, and a surge in investment dedicated to rare disease research. Key trends expected over the forecast period encompass the evolution of personalized therapies, an uptick in orphan drug approvals, significant advancements in subcutaneous drug delivery, the emergence of on-demand treatment solutions, and the broadening of hospital and retail pharmacy networks.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp
What Leading Drivers Are Supporting The Hereditary Angioedema Therapeutics Market Expansion?
The anticipated rise in healthcare spending is projected to propel the expansion of the hereditary angioedema therapeutics market in the future. Healthcare expenditure signifies the overall sum of resources, particularly financial ones, allocated to healthcare products and services within a defined timeframe and geographic region. Enhanced healthcare spending facilitates greater investment in research and development efforts aimed at comprehending the root causes of hereditary angioedema and devising novel treatment options. As an illustration, data from June 2025 by the US federal agency, the Centers for Medicare & Medicaid Services (CMS), indicated that the National Health Expenditure (NHE) expanded by 7.5% to reach $4.9 trillion in 2023, equating to $14,570 per individual, and represented 17.6% of the Gross Domestic Product (GDP). In 2023, hospital spending increased by 10.4% to $1,519.7 billion, surpassing the 3.2% growth observed in 2022. Consequently, the growing healthcare expenditure is serving as a catalyst for the expansion of the hereditary angioedema therapeutics market.
What Are The Key Segment Divisions In The Hereditary Angioedema Therapeutics Market Segment Structure?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-Demand
What Trends Are Affecting The Growth Of The Hereditary Angioedema Therapeutics Market?
Leading companies within the hereditary angioedema (HAE) therapeutics market are actively creating advanced treatments, such as oral plasma kallikrein inhibitors, to improve patient care and provide effective, immediate options for managing HAE attacks, ultimately enhancing patient well-being and life quality. These oral plasma kallikrein inhibitors are medications taken by mouth that work by blocking the plasma kallikrein enzyme, aiding in the control and reduction of the intensity of hereditary angioedema episodes. For example, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical firm, received a New Drug Application acceptance from the US Food and Drug Administration for Sebetralstat, intending to offer HAE patients a more convenient, non-invasive treatment alternative compared to intravenous or subcutaneous drugs. This innovation addresses the increasing need for rapid, effective oral therapies that can be administered instantly during a hereditary angioedema attack.
Which Organizations Are Engaged In The Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market are Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., Dyax Corp., Pharvaris N.V., Kedrion Biopharma Inc., Shire Pharmaceuticals, Octapharma AG, Pharmalink AB, Sobi AB, OctoPharma USA, HAE Pharma, Argenx SE, ImmunoGen Inc., Ionis Pharmaceuticals (for pipeline HAE therapies), PharmAthene Inc., BioMarin Pharmaceutical Inc.
Get The Full Hereditary Angioedema Therapeutics Market Report:
Which Region Dominates The Hereditary Angioedema Therapeutics Market By Market Share?
North America was the largest region in the global hereditary angioedema therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hereditary Angioedema Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2026, By The Business Research Company
Hereditary Angioedema Therapeutics Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Angina Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model